New product newswire
A synthetic cannabinoid agonist has received approval for marketing in the United States for the treatment of nausea and vomiting associated with cancer chemotherapy.
RX
NEW DRUGS
A synthetic cannabinoid agonist has received approval for marketing in the United States for the treatment of nausea and vomiting associated with cancer chemotherapy. Cesamet (CII) (nabilone) Capsules interact with the part of the nervous system that regulates nausea and vomiting, and their long-lasting effects allow the drug to be taken less frequently than some other treatments. Cesamet is available from Valeant Pharmaceuticals, Costa Mesa, Calif., (800) 548-5100.
NEW DOSAGE STRENGTH
The antibiotic Keflex (cephalexin capsules, USP) is now available in 750-mg strength. From Advancis Pharmaceutical Corp., Germantown, Md., (301) 944-6600, the oral cephalosporin can now be prescribed for a more convenient twice-daily use (1500 mg) for the treatment of a variety of infections. Keflex had already been approved in strengths of 250 and 500 mg.
Baxter Healthcare Corp., Deerfield, Ill., (847) 948-2000, is introducing an ultra-high dosage strength of Advate (antihemophilic factor [recombinant], plasma/albumin free method [rAHF-PFM]). This therapy, free of blood-based additives, is approved for the prevention and control of bleeding episodes in patients with hemophilia A. Its higher strength carries a reduced infusion volume and requires shorter mixing time, according to the company.
NEW GENERICS
Barr Laboratories, Woodcliff Lake, N.J., (201) 930-3300, has received FDA approval to market a fourth strength in its Claravis acne medication line. Isotretinoin capsules, USP, will now be available in 30-mg strength, adding to Barr's existing line of Claravis 10-, 20-, and 40-mg capsules. According to the company, the new product will compete with Ranbaxy's Sotret in the same strength. The drug is indicated for treatment of severe recalcitrant nodular acne.
OTC
Cincinnati-based Procter & Gamble, (513) 983-1100, has launched Crest Pro-Health Toothpaste. Combining stannous fluoride and sodium hexametaphosphate, the all-new dentifrice protects against seven common oral health problems: gingivitis; tartar; plaque; sensitivity to cold, heat, acids, sweets, or contact; stains; cavities; and bad breath. The product will be available in two flavors: clean mint and cinnamon.
